Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Primaquine MeSH Descriptor Data 2025


MeSH Heading
Primaquine
Tree Number(s)
D03.633.100.810.050.650
Unique ID
D011319
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D011319
Scope Note
An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
Entry Term(s)
Primacin
Primaquine Diphosphate
Primaquine Phosphate
Pharm Action
Antimalarials
Registry Numbers
MVR3634GX1
H0982HF78B
63-45-6
0
Related Numbers
63-45-6
90-34-6
H0982HF78B
CAS Type 1 Name
1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-
NLM Classification #
QV 258
Date Established
1966/01/01
Date of Entry
1999/01/01
Revision Date
2017/05/24
Primaquine Preferred
Primaquine Phosphate Narrower
Primaquine Diphosphate Narrower
Primacin Narrower
page delivered in 0.123s